Vpriv market forecast points to growth in rare disease therapy
The Vpriv market is expanding on stronger diagnosis rates, broader access to rare disease treatments and rising investment in personalized medicine. North America was the largest regional market in 2025, according to The Business Research Company’s 2026 global market report.
Why it matters: - Vpriv is a niche therapy for Gaucher disease type 1, so market growth depends on rare disease diagnosis, specialist care access and healthcare spending. - The report points to wider use of enzyme replacement therapy and personalized treatment approaches as central forces shaping demand through 2035.
What happened: - The Business Research Company published its Vpriv Market Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report says North America was the largest Vpriv market in 2025. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - A free sample is available here. - The full report is available here.
The details: - Vpriv, or velaglucerase alfa, is a recombinant enzyme replacement therapy for the long-term management of Gaucher disease type 1. - The therapy replaces the missing or deficient glucocerebrosidase enzyme. - Vpriv helps clear the buildup of fatty substances linked to the disease and reduces symptoms. - Historical market growth was supported by wider clinical acceptance of enzyme replacement therapies, better Gaucher disease diagnosis rates, more recombinant biologics, more specialty infusion centers and greater physician familiarity with lysosomal disorders. - Future growth is expected to come from improved access to rare disease treatments, more investment in next-generation enzyme therapies, stronger demand for personalized dosing and advances in recombinant protein manufacturing. - The report highlights wider adoption of enzyme replacement therapy, longer-term rare disease care, broader use of recombinant enzyme technology and more focus on disease progression control as key trends. - Rising global healthcare spending is a major growth driver for the market. - The UK Office for National Statistics reported a 5.6% rise in total healthcare expenditure from 2022 to 2023, compared with 0.9% growth the year before. - The report also points to growing acceptance of biologics as a market driver. - The US National Institutes of Health said the FDA approved 50 novel drugs in 2024, including 16 biologics. - The Personalized Medicine Coalition reported that the FDA approved 16 new personalized treatments for rare disease patients in 2023, up from six in 2022.
Between the lines: - The report frames Vpriv as part of a broader shift toward targeted therapies for rare diseases, not as a mass-market drug. - The emphasis on biologics and personalized medicine suggests future competition will be shaped by precision treatment capabilities, not just volume. - Regional leadership in North America likely reflects stronger diagnosis rates, specialist infrastructure and reimbursement capacity.
What's next: - The report expects the market to keep expanding through 2035 as access to rare disease care improves. - The Business Research Company says its 2026 reports now include market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel dashboards, market hotspot infographics and future trend analysis. - More information is available on the company’s LinkedIn page and social media channels.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
Governance News: Africa
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.